Navigation Links
Coherent, Inc. Reports Strong First Fiscal Quarter Results and Raises Annual Sales Guidance
Date:1/28/2010

nd net loss of $14.7 million, or $0.61 per share, for the first quarter of fiscal 2009.  Non-GAAP net income for the first quarter of fiscal 2010 was $5.1 million or $0.21 per diluted share and non-GAAP net income for the first quarter of fiscal 2009 was $8.6 million, or $0.36 per diluted share. Please see the reconciliation of GAAP to non-GAAP results included on the last page of our release.

Net sales for the fourth quarter of fiscal 2009 were $107.6 million and net loss, on a GAAP basis, was $4.5 million ($0.18 per share).  Non-GAAP net loss for the fourth quarter of fiscal 2009 was $0.9 million or $0.04 per share.  

Bookings received during the three months ended January 2, 2010 of $158.4 million increased 53.3% from $103.3 million in the same prior year period and increased by 18.7% compared to bookings of $133.4 million in the immediately preceding quarter.  The book-to-bill ratio was 1.3, resulting in backlog of $202.8 million at January 2, 2010 compared to a backlog of $164.3 million at October 3, 2009 and a backlog of $162.0 million at December 27, 2008.

We ended the quarter with cash and short term investments of $240.6 million, a decrease of $3.0 million from cash and short term investments of $24
'/>"/>

SOURCE Coherent, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Coherent, Inc. to Webcast Third Fiscal Quarter 2008 Results
2. Coherent, Inc. Announces Termination of SEC Informal Inquiry
3. Coherent, Inc. to Webcast Fourth Fiscal Quarter 2007 Results
4. Coherent, Inc. Receives Expected Letter from NASDAQ
5. Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share
6. Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer
7. Medicago reports positive Phase I results for its avian flu pandemic vaccine
8. Neogen Reports 18% Increase in Net Income
9. EntreMed Reports Receipt of Third Quarter Royalty Payment
10. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
11. YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)...  Schulman Associates IRB, Inc., the industry-leading central IRB ... lease on Laboratory Drive in the heart of ... location will house review board and service staff, which ... and customer service to clients. CBRE ... the deal, while Capital Associates Management, LLC represented the ...
(Date:4/16/2015)... 16, 2015 OncoTAb, Inc., ... (UNC Charlotte) spin-out company, announced today the appointment ... M.D., as Chief Operating Officer (COO). Cooper brings ... in developing clinical diagnostic and biotechnology platforms in ... , Cooper’s extensive career transcends the field of ...
(Date:4/16/2015)... - Portage Biotech Inc. ("Portage" or "the Company" )) ... to announce that the Company will be presenting  at ... be held in London, UK . ... James Mellon , a director of Portage, will ... programs at its subsidiaries, Portage Pharmaceuticals Ltd. ("PPL"), and ...
(Date:4/16/2015)... , April 16, 2015 ... the Russian pharmaceutical investment and R&D group, ... collaboration for research, development and commercialization of ... with the intention to stimulate the ...      (Logo: http://photos.prnewswire.com/prnh/20150416/739742-a) ,     (Logo: ...
Breaking Biology Technology:Schulman IRB to Open Office in Research Triangle Park, N.C. 2OncoTAb Names Dr. David L. Cooper as COO 2Portage to Present at Master Investor 2015 in London, UK 2Portage to Present at Master Investor 2015 in London, UK 3Portage to Present at Master Investor 2015 in London, UK 4Lancet and ChemRar High Tech Center Have Announced a Partnership in the Development and Production of Novel Drugs in Russia 2
... Wis. Now that Metavante Corporation ... healthcare payments distribution firm, the company says it ... hiring a new president. , ,John Reynolds, who ... director for health benefits services at Wells Fargo ...
... Technologies Inc. said it has reached an agreement with ... Third Wave's patent lawsuit. , ,Third Wave said that no ... terms of the agreement. , ,This leaves Third Wave with ... Corp. is on appeal after a court awarded Third Wave ...
... days away from the Olympics of Biotechnology happening in Chicago! For ... normally in June?", you would traditionally be right. The annual BIO ... , ,The BIO organization made a strategic decision this ... for a couple of key reasons: , ,1. Avoid coinciding with ...
Cached Biology Technology:42 days until the 2006 Olympics of Biotechnology in Chicago 242 days until the 2006 Olympics of Biotechnology in Chicago 342 days until the 2006 Olympics of Biotechnology in Chicago 442 days until the 2006 Olympics of Biotechnology in Chicago 5
(Date:3/31/2015)... 31, 2015   Guidepoint , a leading global ... Post-Surgical Pain Management TRACKER, part of the Guidepoint ... in the medical device and therapeutics markets. The Post-Surgical ... treatment volumes, market share, and adoption rates across three ... joint surgery. The Post-Surgical Pain Management TRACKER ...
(Date:3/24/2015)... Research and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) ... Recognition Market 2015-2019" report to their offering. ... to grow at a CAGR of 23.5 percent over ... present scenario and the growth prospects of the Global ... the market size, the report considers the revenue generated ...
(Date:3/24/2015)... Fla. , March 24, 2015   ... management solutions, today announced that its U.are.U ® ... accessory retailer Goorin Bros . to achieve ... biometrics-based solution secures access to the POS terminal, ... increased risk of data breaches. ...
Breaking Biology News(10 mins):Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2
... Duke University-led study has documented dramatic, natural short-term increases in ... "The natural short-term variability in acidity we observed over the ... ocean as a whole and may already be exerting added ... that are especially susceptible to changes in pH," said Zackary ...
... the Florida campus of The Scripps Research Institute have revealed ... form of muscular dystrophy, myotonic dystrophy type 2, and have ... counter those defectsand reverse the disease. "This the first ... disease has been determined," said TSRI Associate Professor Matthew Disney, ...
... bulging or protruding intervertebral discs occupies the intervertebral foramen, ... nerve root fibers is reduced, fiber bundles gathered together ... Dr. Xin Tian and colleagues from the Second Hospital ... to use diffusion tensor tractography to reveal spinal nerve ...
Cached Biology News:Local factors cause dramatic spikes in coastal ocean acidity 2Scientists uncover image of muscular dystrophy defect & design targeted drug candidates 2
...
Jak3 Antibody Ship: Hot Store: -20 C...
WASF2 Immunogen: WASF2 (NP_008921, 73 a.a. ~ 173 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Applications: Western blotting Stability: Room temperature, indefinitely ...
Biology Products: